Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement

Rhea-AI Summary

Biofrontera, Inc. (Nasdaq: BFRI; BFRIW) has entered a securities purchase agreement with an institutional investor for 3,419,000 shares of common stock at $2.75 per share, plus warrants for an additional 3,419,000 shares. The total gross proceeds are projected to be approximately $9.4 million, with the offering expected to close by May 17, 2022.

Roth Capital Partners and The Benchmark Company are the exclusive placement agents. The company is obligated to file a registration statement for resale within 15 days of the deal's closing.

Positive

• The private placement is expected to raise approximately $9.4 million, enhancing liquidity.
• Warrants provide potential for additional capital through future stock sales.

Negative

• The offering dilutes existing shareholders due to the issuance of new shares.
• Securities are offered under Regulation D, limiting immediate resale opportunities.

WOBURN, MA., May 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 3,419,000 shares of common stock, in a private placement. The purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $2.75. The warrants have an exercise price of $2.77 per share, will be exercisable six months after issue date, and will expire five and one-half years from the issuance date.

Roth Capital Partners and The Benchmark Company are acting as the exclusive placement agents for the private offering.

The gross proceeds from the private placement offering are expected to be approximately $9.4 million. The private offering is expected to close on or about May 17, 2022, subject to the satisfaction of customary closing conditions.

The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder, and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

Under an agreement with the investor, the Company is required to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors and shares of common stock underlying the warrants described above within 15 calendar days and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 90 days in the event of a “full review” by the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Biofrontera, Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the gross proceeds of the private placement, closing of the private placement and the future registration of shares issued in connection with the private placement. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz^® in combination with BF-RhodoLED^® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz^® in combination with BF-RhodoLED^® is consistent with the Company’s expectations; the Company’s ability to complete the transition to a public company; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Contacts

Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com

LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com

FAQ

What is the significance of the Biofrontera securities purchase agreement announced on May 16, 2022?

Biofrontera has entered an agreement to sell 3,419,000 shares at $2.75 each, projected to raise $9.4 million.

What will the proceeds from the Biofrontera private placement be used for?

The proceeds are intended to enhance liquidity and support business operations.

When is the expected closing date for Biofrontera's private placement?

The offering is expected to close on or about May 17, 2022.

What are the terms of the warrants issued in the Biofrontera deal?

The warrants allow the purchase of shares at $2.77 per share, exercisable six months after issuance.